Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.

Hello, and welcome to the Second Quarter Fiscal Year 2025 Cardinal Health Inc. Earnings Conference Call. My name is George, and I'll be coordinator for today's event. Please note, this conference is ...

Reports Q2 revenue $55.26B, consensus $54.97B. “We delivered strong second quarter financial results while taking significant strategic and ...

Consensus $7.86. The company said, “The company raised its fiscal 2025 guidance range for non-GAAP diluted earnings per share attributable to ...

Citi analyst Daniel Grosslight increased the price target for Cardinal Health (NYSE:CAH) shares to $130 from the previous $129, while keeping a Neutral rating on the stock. The adjustment follows ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

He has covered insurance for a decade, including auto, home, life and health. Before cove... Ashlee is an insurance editor, journalist and business professional with an MBA and more than 17 years ...

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune cells in ...